Brain Tumor Treatment Companies Strategic Expansion Initiatives

Top Vendors in the Brain Tumor Treatment Market & Growth 2026-2035

Merck & Co., Inc.

Headquarters: New Jersey, USA
Offerings: Immunotherapies (e.g., Keytruda), targeted therapies, and oncology research for various cancers, including brain tumors

Bristol-Myers Squibb

Headquarters: New York, USA
Offerings: Immunotherapies, CAR T-cell therapies, and checkpoint inhibitors used in oncology treatments

AstraZeneca

Headquarters: Cambridge, United Kingdom
Offerings: Targeted therapies, biologics, and precision medicine solutions for solid tumors, including glioblastoma research

Bayer AG

Headquarters: Leverkusen, Germany
Offerings: Chemotherapy drugs, anti-angiogenic agents, and oncology R&D, including brain tumor therapies

Eisai Co., Ltd.

Headquarters: Tokyo, Japan
Offerings: Oncology-focused therapies, including glioblastoma treatments and targeted drugs in clinical trials

Amgen Inc.

Headquarters: California, USA
Offerings: Biologics, immuno-oncology therapies, and research in tumor-targeted treatments

Value Chain Analysis

R&D 

• Brain tumor R&D emphasizes precision medicine using genomics for personalized treatment approaches.
• Immunotherapy development focuses on CAR T-cells and vaccines to strengthen immune response.
• Novel drug delivery systems help improve drug penetration across the blood–brain barrier.
• Advanced radiation technologies enable more accurate tumor targeting.
• Key players: Roche, Novartis, Bristol Myers Squibb, Gilead Sciences, Varian Medical Systems, Hitachi

Regulatory Approvals

• Regulatory bodies like the FDA and EMA approve various brain tumor treatments, ensuring safety and effectiveness.
• Approved therapies include chemotherapy drugs, targeted therapies, and medical devices used in treatment and surgery.
• These approvals support wider patient access and adoption of advanced treatment options.
• Key players: Pfizer, Merck, AstraZeneca, Medtronic, Elekta

Patient Support and Services

• Counseling and education: Patients receive guidance, resources, and support through programs and support groups for emotional well-being.
• Treatment navigation: Patient navigators help guide individuals through therapy options, clinical trials, and care decisions.
• Specialized care: Multidisciplinary teams including neuro-oncologists, surgeons, and allied health professionals provide coordinated treatment.
• Financial and logistical support: Assistance programs help cover treatment costs and manage logistical challenges.
• Key players: Novartis, Roche, St. Jude Children’s Research Hospital, CancerCare, Brain Tumour Research

Market Growth

The global brain tumor treatment market size was estimated at USD 3.58 billion in 2025 and is predicted to increase from USD 3.84 billion in 2026 to approximately USD 7.21 billion by 2035, expanding at a CAGR of 7.24% from 2026 to 2035.

What are the Recent Developments in the Brain Tumor Treatment Market?

• In November 2025, the 5G clinical trial in the U.K. was launched to accelerate glioblastoma drug development. Addressing long-standing challenges like the blood-brain barrier and limited patient numbers, the trial supported by Cancer Research U.K. aims to overcome decades of slow progress and provide faster treatment options for brain cancer patients.
• In August 2025, Jazz Pharmaceuticals received FDA approval for Modeyso (dordaviprone), the first therapy for recurrent H3 K27M-mutant diffuse midline glioma, a rare and aggressive brain tumor affecting children and young adults. Approval was based on a 22% response rate in 50 patients, providing a significant new option for those with very limited treatments.

Become a valued research partner with us, please feel free to contact us at sales@towardshealthcare.com